Study to Evaluate the Safety of UF-KURE-BCMA CAR T-Cells in Advanced Myeloma

by | May 28, 2026 | Clinical Trials | 0 comments

​ Conditions: Multiple Myeloma in Relapse; Multiple Myeloma, Refractory

Interventions: Biological: Administration of CAR T-cells at 3 different dose levels

Sponsors: Kure Cells, INC; CellServe LLC; Roya Clinical

Not yet recruiting Conditions: Multiple Myeloma in Relapse; Multiple Myeloma, Refractory
Interventions: Biological: Administration of CAR T-cells at 3 different dose levels
Sponsors: Kure Cells, INC; CellServe LLC; Roya Clinical
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *